Study S000641

The Differential Effects of Diabetes Therapy on Inflammation

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT02150707
Study type: OBSERVATIONAL
Status: COMPLETED
Enrollment: 17
Start: 2014-05
Primary completion: 2015-12
Lead sponsor: University College Dublin
Conditions: Diabetic Nephropathy; Type 2 Diabetes
Interventions: DRUG:Dipeptidyl-Peptidase IV Inhibitors; DRUG:Glucagon-Like Peptide 1
Results posted: FALSE

Registered primary outcomes

Monocyte:chemoattractant protein 1 (MCP-1):creatinine ratio [6 months]

Linked records (2)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0021526	Glucagon-like peptide 1 analogue therapy directly modulates innate immune-mediated inflammation in individuals with type 2 diabetes mellitus. Hogan AE, Diabetologia	2014	Preclinical	PMID 24362727 DOI	registry reference BACKGROUND:24362727
R0027133	Effect of exenatide on inflammatory and oxidative stress markers in patients with type 2 diabetes mellitus. Wu JD, Diabetes technology & therapeutics	2011	Randomized trial	PMID 21284481 DOI	registry reference BACKGROUND:21284481